Johannesburg, Oct 16: South Africa has made a significant move in the fight against HIV/AIDS by introducing a long-acting injectable drug, Lenacapavir, Health Minister Aaron Motsoaledi announced. Speaking in Johannesburg, Motsoaledi called the rollout a “pivotal moment” for the nation, emphasizing that the injection will enhance South Africa’s HIV prevention strategy.

The minister highlighted the country’s progress over the past two decades in tackling high HIV infection rates, with about eight million people currently living with the virus. Lenacapavir strengthens ongoing efforts and builds on years of prevention and treatment achievements.

South Africa secured an initial allocation of Lenacapavir through a Global Fund grant, which will cover only a fraction of the need over the first two years. The $29 million catalytic investment will provide around 456,000 initiations, equaling 912,000 doses.

In 2023, 149,000 people were diagnosed with HIV, with women and adolescent girls being the most affected. The injection, administered twice a year, is expected to improve adherence among high-risk groups and address persistent challenges in HIV prevention.

The initial rollout will prioritize groups most vulnerable to HIV, including adolescent girls, pregnant and breastfeeding mothers, female sex workers, and men who have sex with men.